Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 4
2014 12
2015 15
2016 14
2017 14
2018 25
2019 21
2020 21
2021 21
2022 15
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts.
Liu ZS, Sinha S, Bannister M, Song A, Arriaga-Gomez E, McKeeken AJ, Bonner EA, Hanson BK, Sarchi M, Takashima K, Zong D, Corral VM, Nguyen E, Yoo J, Chiraphapphaiboon W, Leibson C, McMahon MC, Rai S, Swisher EM, Sachs Z, Chatla S, Stirewalt DL, Deeg HJ, Skorski T, Papapetrou EP, Walter MJ, Graubert TA, Doulatov S, Lee SC, Nguyen HD. Liu ZS, et al. Cancer Res. 2024 Feb 15;84(4):577-597. doi: 10.1158/0008-5472.CAN-23-3239. Cancer Res. 2024. PMID: 37967363
An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
Xiang J, Devenport JM, Carter AJ, Staser KW, Kim MY, O' Neal J, Ritchey JK, Rettig MP, Gao F, Rettig G, Turk R, Lee BH, Cooper ML, DiPersio JF. Xiang J, et al. Leukemia. 2023 Dec;37(12):2448-2456. doi: 10.1038/s41375-023-02039-z. Epub 2023 Oct 5. Leukemia. 2023. PMID: 37798328 Free PMC article.
Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer.
Jacobs MT, Wong P, Zhou AY, Becker-Hapak M, Marin ND, Marsala L, Foster M, Foltz JA, Cubitt CC, Tran J, Russler-Germain DA, Neal C, Kersting-Schadek S, Chang L, Schappe T, Pence P, McClain E, Zevallos JP, Rich JT, Paniello RC, Jackson RS, Pipkorn P, Adkins DR, DeSelm CJ, Berrien-Elliott MM, Puram SV, Fehniger TA. Jacobs MT, et al. Clin Cancer Res. 2023 Oct 13;29(20):4196-4208. doi: 10.1158/1078-0432.CCR-23-0156. Clin Cancer Res. 2023. PMID: 37556118 Free PMC article.
Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia.
de Jonge PKJD, van Hauten PMM, Janssen LD, de Goede AL, Berrien-Elliott MM, van der Meer JMR, Mousset CM, Roeven MWH, Foster M, Blijlevens N, Hobo W, Fehniger TA, Jansen JH, Schaap NPM, Dolstra H. de Jonge PKJD, et al. Cancer Immunol Immunother. 2023 Oct;72(10):3323-3335. doi: 10.1007/s00262-023-03492-6. Epub 2023 Jul 21. Cancer Immunol Immunother. 2023. PMID: 37477653 Free PMC article.
Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc.
O'Neal J, Cooper ML, Ritchey JK, Gladney S, Niswonger J, González LS, Street E, Haas GJ, Carter A, Amayta PN, Gao F, Lee BH, Choi D, Berrien-Elliott M, Zhou A, Fehniger TA, Rettig MP, DiPersio JF. O'Neal J, et al. Blood Adv. 2023 Oct 24;7(20):6009-6022. doi: 10.1182/bloodadvances.2023010032. Blood Adv. 2023. PMID: 37399471 Free PMC article.
159 results